Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/29335
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWalker L.en
dc.contributor.authorLi H.en
dc.contributor.authorTerry M.B.en
dc.contributor.authorAntoniou A.C.en
dc.contributor.authorPhillips K.-A.en
dc.contributor.authorKast K.en
dc.contributor.authorMooij T.M.en
dc.contributor.authorEngel C.en
dc.contributor.authorNogues C.en
dc.contributor.authorStoppa-Lyonnet D.en
dc.contributor.authorLasset C.en
dc.contributor.authorBerthet P.en
dc.contributor.authorMari V.en
dc.contributor.authorCaron O.en
dc.contributor.authorBarrowdale D.en
dc.contributor.authorFrost D.en
dc.contributor.authorBrewer C.en
dc.contributor.authorEvans D.G.en
dc.contributor.authorIzatt L.en
dc.contributor.authorSide L.en
dc.contributor.authorTischkowitz M.en
dc.contributor.authorRogers M.T.en
dc.contributor.authorPorteous M.E.en
dc.contributor.authorSnape K.en
dc.contributor.authorMeijers-Heijboer H.E.J.en
dc.contributor.authorGille J.J.P.en
dc.contributor.authorBlok M.J.en
dc.contributor.authorHoogerbrugge N.en
dc.contributor.authorDaly M.B.en
dc.contributor.authorAndrulis I.L.en
dc.contributor.authorBuys S.S.en
dc.contributor.authorJohn E.M.en
dc.contributor.authorMcLachlan S.-A.en
dc.contributor.authorFriedlander M.en
dc.contributor.authorTan Y.Y.en
dc.contributor.authorOsorio A.en
dc.contributor.authorCaldes T.en
dc.contributor.authorJakubowska A.en
dc.contributor.authorSimard J.en
dc.contributor.authorSinger C.F.en
dc.contributor.authorOlah E.en
dc.contributor.authorNavratilova M.en
dc.contributor.authorForetova L.en
dc.contributor.authorGerdes A.-M.en
dc.contributor.authorRoos-Blom M.-J.en
dc.contributor.authorArver B.en
dc.contributor.authorOlsson H.en
dc.contributor.authorSchmutzler R.K.en
dc.contributor.authorHopper J.L.en
dc.contributor.authorMilne R.L.en
dc.contributor.authorEaston D.F.en
dc.contributor.authorVan Leeuwen F.E.en
dc.contributor.authorRookus M.A.en
dc.contributor.authorAndrieu N.en
dc.contributor.authorGoldgar D.E.en
dc.date.accessioned2021-05-14T09:54:45Zen
dc.date.available2021-05-14T09:54:45Zen
dc.date.copyright2020en
dc.date.created20200415en
dc.date.issued2020-04-15en
dc.identifier.citationCancer Epidemiology Biomarkers and Prevention. 29 (2) (pp 368-378), 2020. Date of Publication: 01 Feb 2020.en
dc.identifier.issn1055-9965en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/29335en
dc.description.abstractBackground: Tobacco smoking and alcohol consumption have been intensively studied in the general population to assess their effects on the risk of breast cancer, but very few studies have examined these effects in BRCA1 and BRCA2 mutation carriers. Given the high breast cancer risk for mutation carriers and the importance of BRCA1 and BRCA2 in DNA repair, better evidence on the associations of these lifestyle factors with breast cancer risk is essential. Method(s): Using a large international pooled cohort of BRCA1 and BRCA2 mutation carriers, we conducted retrospective (5,707 BRCA1 mutation carriers and 3,525 BRCA2 mutation carriers) and prospective (2,276 BRCA1 mutation carriers and 1,610 BRCA2 mutation carriers) analyses of alcohol and tobacco consumption using Cox proportional hazards models. Result(s): For both BRCA1 and BRCA2 mutation carriers, none of the smoking-related variables was associated with breast cancer risk, except smoking for more than 5 years before a first full-term pregnancy (FFTP) when compared with parous women who never smoked. For BRCA1 mutation carriers, the HR from retrospective analysis (HRR) was 1.19 [95% confidence interval (CI), 1.02-1.39] and the HR from prospective analysis (HRP) was 1.36 (95% CI, 0.99-1.87). For BRCA2 mutation carriers, smoking for more than 5 years before an FFTP showed an association of a similar magnitude, but the confidence limits were wider (HRR = 1.25; 95% CI, 1.01-1.55 and HRP = 1.30; 95% CI, 0.83-2.01). For both carrier groups, alcohol consumption was not associated with breast cancer risk. Conclusion(s): The finding that smoking during the prereproductive years increases breast cancer risk for mutation carriers warrants further investigation.Copyright © 2020 American Association for Cancer Research.en
dc.languageEnglishen
dc.languageenen
dc.publisherAmerican Association for Cancer Research Inc.en
dc.relation.ispartofCancer Epidemiology Biomarkers and Preventionen
dc.subject.meshgene mutation-
dc.subject.meshhazard ratio-
dc.subject.meshheterozygote-
dc.subject.meshpregnancy-
dc.subject.meshfirst full term pregnancy-
dc.subject.meshBRCA2 protein-
dc.subject.meshBRCA1 protein-
dc.subject.meshproportional hazards-
dc.subject.meshalcohol consumption-
dc.subject.meshbreast cancer-
dc.subject.meshcancer risk-
dc.subject.meshcigarette smoking-
dc.subject.meshconfidence interval-
dc.titleAlcohol consumption, cigarette smoking, and risk of breast cancer for BRCA1 and BRCA2 mutation carriers: Results from the BRCA1 and BRCA2 cohort consortium.en
dc.typeArticleen
dc.identifier.affiliationMonash University - School of Clinical Sciences at Monash Health-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1158/1055-9965.EPI-19-0546-
dc.publisher.placeUnited Statesen
dc.identifier.pubmedid31792088 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31792088]en
dc.identifier.source2005134402en
dc.identifier.institution(Li, Goldgar) Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, United States (Terry) Department of Epidemiology, Columbia University, New York, NY, United States (Terry) Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, United States (Antoniou, Barrowdale, Frost, Easton) Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, United Kingdom (Phillips, Hopper, Milne) Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, VIC, Australia (Phillips) Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia (Phillips) Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (Kast) Department of Gynecology and Obstetrics, Medical Faculty, University Hospital Carl Gustav Carus, Technische Universitat, Dresden, Germany (Kast) National Center for Tumor Diseases (NCT) Partner Site Dresden, Germany (Kast) German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany (Mooij, Roos-Blom, Van Leeuwen, Rookus) Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands (Engel) Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Germany (Nogues) Institut Paoli-Calmettes, Departement d'Anticipation et de Suivi des Cancers, Oncogenetique Clinique and Aix Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France (Stoppa-Lyonnet) Institut Curie, Service de Genetique Medicale, Paris, France (Stoppa-Lyonnet) Inserm, U830, Universite Paris Descartes, Paris, France (Lasset) Unite de Prevention et Epidemiologie Genetique, Centre Leon Berard - Lyon, UMR CNRS 5558, Universite de Lyon, Lyon, France (Berthet) Departement de Biopathologie, Oncogenetique Clinique, Centre Francois Baclesse, Caen, France (Mari) CLCC Antoine Lacassagne, Departement d'Hematologie - Oncologie Medicale, Nice, France (Caron) Departement de Medecine, Gustave Roussy Hopital Universitaire, Villejuif, France (Brewer) Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom (Evans) Genomic Medicine, NIHR Manchester Biomedical Research Centre, Manchester Academic Health Sciences Centre, Division of Evolution and Genomic Sciences, Manchester University, Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom (Izatt) Clinical Genetics, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom (Side) Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, United Kingdom (Walker) Oxford Regional Genetics Service, Churchill Hospital, Oxford, United Kingdom (Tischkowitz) University of Cambridge, Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, Cancer Research UK Cambridge Center, Cambridge Biomedical Campus, Cambridge, United Kingdom (Rogers) All Wales Medical Genetics Services, University Hospital of Wales, Cardiff, United Kingdom (Porteous) South East of Scotland Regional Genetics Service, Western General Hospital, Edinburgh, United Kingdom (Snape) Medical Genetics Unit, St. george'S, University of London, London, United Kingdom (Meijers-Heijboer, Gille) Department of Clinical Genetics, VU University Medical Center, Amsterdam, Netherlands (Blok) Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, Netherlands (Hoogerbrugge) Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands (Daly) Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, United States (Andrulis) Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada (Andrulis) Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada (Buys) Department of Medicine, University of Utah Health Sciences Center, Huntsman Cancer Institute, Salt Lake City, UT, United States (John) Stanford University School of Medicine, Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, United States (McLachlan) Department of Medicine, St. Vincent's Hospital, University of Melbourne, Parkville, VIC, Australia (McLachlan) Department of Medical Oncology, St. Vincent's Hospital, Fitzroy, VIC, Australia (Friedlander) Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW, Australia (Friedlander) Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (Tan, Singer) Department of OB/GYN, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (Osorio) Human Genetics Group, Spanish National Cancer Centre (CNIO), Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Caldes) Molecular Oncology Laboratory, Hospital Clinico San Carlos, IdISSC, CIBERONC (ISCIII), Madrid, Spain (Jakubowska) Department of Genetics and Pathology, Pomeranian Medical University, Unii Lubelskiej 1, Szczecin, Poland (Jakubowska) Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland (Simard) Genomics Center, Centre Hospitalier Universitaire de Quebec, Universite Laval Research Center, Quebec City, QC, Canada (Olah) Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary (Navratilova, Foretova) Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, Czechia (Gerdes) Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden (Arver) Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark (Arver, Olsson) Department of Oncology, Lund University Hospital, Lund, Sweden (Schmutzler) Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany (Schmutzler) Center for Molecular Medicine Cologne(CMMC), University of Cologne, Cologne, Germany (Milne) Division of Cancer Epidemiology and Intelligence, Cancer Council Victoria, Melbourne, Australia (Milne) Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia (Easton) Centre for Cancer Genetic Epidemiology, Department of Oncology, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, United Kingdom (Andrieu) INSERM, U900, Paris, France (Andrieu) Institut Curie, Paris, France (Andrieu) Mines Paris Tech, Fontainebleau, France (Andrieu) PSL Research University, Paris, France (Goldgar) Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT, United States (Andrieu) Cancer Genetic Epidemiology Team, INSERM Unit 900, Institut Curie, 26 rue d'Ulm, Paris 75005, Franceen
dc.description.addressD.E. Goldgar, University of Utah, School of Medicine, 30 N. Medical Drive, Salt Lake City, UT 84132, United States. E-mail: david.goldgar@hsc.utah.eduen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2020 Elsevier B.V., All rights reserved.en
dc.identifier.authoremailGoldgar D.E.; david.goldgar@hsc.utah.edu Andrieu N.; nadine.andrieu@curie.fren
dc.description.grantOrganization: (ERDF) *European Regional Development Fund* Organization: *Canadian Institutes of Health Research* Organization No: 501100000024 Country: Canada Organization: *Cancerfonden* Organization No: 501100002794 Country: Sweden Organization: *Deutsches Krebsforschungszentrum* Organization No: 100008658 Country: Germany Organization: *European Commission* Organization No: 501100000780 Organization: *Fondation de France* Organization No: 501100004431 Country: France Organization: *Institute of Cancer Research* Organization No: 501100000027 Country: Canada Organization: *NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research* Organization No: 100014461 Country: United Kingdom Organization: *Royal Marsden NHS Foundation Trust* Organization No: 100012139 Country: United Kingdom No: 110837 Organization: *Deutsche Krebshilfe* Organization No: 501100005972 Country: Germany No: 145684 Organization: *National Health and Medical Research Council* Organization No: 501100000925 Country: Australia No: 288704 Organization: *National Health and Medical Research Council* Organization No: 501100000925 Country: Australia No: 454508 Organization: *National Health and Medical Research Council* Organization No: 501100000925 Country: Australia No: C12292/A11174 Organization: *Cancer Research UK* Organization No: 501100000289 Country: United Kingdom No: C12292/A20861 Organization: *Cancer Research UK* Organization No: 501100000289 Country: United Kingdom No: C1287/A10118 Organization: *Cancer Research UK* Organization No: 501100000289 Country: United Kingdom No: C1287/A11990 Organization: *Cancer Research UK* Organization No: 501100000289 Country: United Kingdom No: ERC-2011-294576 Organization: *Cancerfonden* Organization No: 501100002794 Country: Sweden No: PSR-SIIRI-701 Organization: *Ministere du Developpement Economique, de l'Innovation et de l'Exportation* Organization No: 100011100 Country: Canadaen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
Appears in Collections:Articles
Show simple item record

Page view(s)

14
checked on Sep 14, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.